Using economic information in health care: Drug selection for hospital formularies;L'utilisation de l'information economique dans le secteur de la sante : Le choix des medicaments a inclure dans les livrets therapeutiques hospitaliers

Journal d'Economie Medicale

Volumn 18, Issue 3-4, 2000, Pages 147-161

  Spath, H M ^a   Allenet, B ^a   Carrere, M O ^a  

^a CENTRE LÉON BÉRARD   (France)

Author keywords

Decision making; Economic infomation; Hospital formulary; Literature review; Phamacoeconomics

Indexed keywords

ARTICLE; CLINICAL PRACTICE; DATA BASE; DECISION MAKING; DRUG ADMINISTRATION; DRUG CHOICE; DRUG DOSE; DRUG EFFICACY; DRUG FORMULARY; DRUG SAFETY; ECONOMIC EVALUATION; HEALTH CARE; PHARMACOECONOMICS; PUBLICATION; QUALITY OF LIFE;

EID: 0033802510     PISSN: 02940736     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (52)

1. Health care CBA/CEA: An update on the growth and composition of the literature
2. Health care CBA and CEA from 1991 to 1996: An updated bibliography
3. Are we ready to use cost-effectiveness analysis in health care decision making? A health services research challenge for clinicians, patients, health care systems and public policy
4. Economic evaluation and health care decision-making
5. Current trends in the use of pharmacoeconomics and outcomes research in Europe
6. Hospital pharmacy decisions, cost containment, and the use of cost-effectiveness analysis
7. Hospital formularies in 1993: Where, why and how?
8. The formulary decision-making process in a US academic medical centre
9. Hospital drug formularies and use of hospital services
10. Enquete sur le concept de comite du medicament
11. Le role dynamique du comite du medicament
12. Politique du gouvernment en matiere de medicament. Maitriser la depense pharmaceutique
13. Hopitaux: La double contrainte
14. Pharmaceutical economy and the economic assessment of drugs in France
15. Overview of pharmacoeconomica and pharmaceutical outcomes evaluations
16. Expanding the role of pharmacists in pharmacoeconomics. Why and how?
17. The status of health technology assessment worldwide. Results of an international survey
18. Interet et actualite d'un numero special sur les aspects economiques du medicament
19. Interrogation multibases. Un outil important pour la recherche biomedicale
20. Economic evaluations in the critical care literature: Do they help us improve the efficiency of our unit?
21. Analysis of the eligibility of published economic evaluations for transfer to a given health care system. Methodological approach and application to the French Health Care System
22. Cost-effectiveness and cost-benefit analyses in the medical literature. Are the methods being used correctly?
23. Efficacy and cost-effectiveness of cancer treatment: Rational allocation of resources based on decision analysis
24. Uses of pharmacoeconomic data by policy makers and pharmaceutical benefit managers
25. Regulation of pharmaceutical prices. A managed care perspective
26. College des Economistes de la Sante. Recommandations de bonnes pratiques des methodes d'evaluation economique des strategies therapeutiques
27. Standardizing economic appraisal of health technology in the european community
28. Guidelines for performing a pharmacoeconomic analysis
29. Guidelines for the authors and peer reviewers of economic submissions to the BMJ
30. Economic evaluation of pharmaceuticals. Science or marketing?
31. Avoiding bias in the conduct and reporting of cost-effectiveness research sponsored by pharmaceutical companies
32. Extrapolation of cost-effectiveness information to local settings
33. Will future pharmacists understand pharmacoeconomic research?
34. The pharmacoeconomist - An emerging specialist in health care institutions
35. European School of Oncology advisory report to the Commission of the European Communities for the 'Europe Against Cancer Programme' cost-effectiveness in cancer care
36. Hospital formularies: Need for continuous intervention
37. Economic, clinical, and humanistic outcomes: A planning model for pharmacoeconomic research
38. Choices of methodology in pharmacoeconomic studies
39. Implementing pharmacoeconomic outcomes management
40. Providing cost-effective therapy using pharmacoeconomic evaluations: The public sector approach
41. Eurassess project subgroup report on dissemination and impact